연구성과로 돌아가기
2023 연구자 정보 (64 / 1135)
※ 컨트롤 + 클릭으로 열별 다중 정렬 가능합니다.
Excel 다운로드
| Author Name | 제1저자 여부 | 교신저자 여부 | Address | ResearcherID | ORCID | Paper Title | WoS Edition | 최상위 JCR(%) | WoS Category | Related Email |
|---|---|---|---|---|---|---|---|---|---|---|
|
Mokatrin, Ahmad (Mokatrin, A) |
|
|
[JCR상위 1.7] Ibrutinib for First-Line Treatment of Chronic Graft-Versus-Host Disease: Results From the Randomized Phase III iNTEGRATE Study | SCIE | 1.7 | ONCOLOGY | dmiklos@stanford.edu; | |||
|
Moon, Hyeong-Gon (Moon, HG) |
G-7724-2011 Moon, Hyeong-Gon |
|
[JCR상위 1.7] Prospective single-arm study of endocrine therapies with ovarian function suppression in premenopausal patients with node-positive early breast cancer with low genomic risk (INTERSTELLAR trial, KBCSG-25) | SCIE | 1.7 | ONCOLOGY | ||||
|
Nam, Sang Eun (Nam, SE) |
|
|
[JCR상위 1.7] Omission of breast surgery for predicted pCR patients with MRI and vacuum-assisted biopsy in breast cancer after neoadjuvant chemotherapy: A multicenter, single-arm, non-inferiority trial (OPTIMIST trial) | SCIE | 1.7 | ONCOLOGY | ||||
|
Negro, Alejandra (Negro, A) |
|
|
[JCR상위 1.7] Outcomes by occurrence of immune-mediated adverse events (imAEs) with tremelimumab (T) plus durvalumab (D) in the phase 3 HIMALAYA study in unresectable hepatocellular carcinoma (uHCC) | SCIE | 1.7 | ONCOLOGY | ||||
|
Neuschwander-Tetri, Brent A. (Neuschwander-Tetri, BA) |
St Louis Univ, Sch Med, St Louis, MO USA |
IST-8116-2023 Neuschwander-Tetri, Brent |
|
[JCR상위 1.7] A phase I/II study of ARO-HSD, an RNA interference therapeutic, for the treatment of non-alcoholic steatohepatitis | SCIE | 1.7 | GASTROENTEROLOGY & HEPATOLOGY | mfyuen@hku.hk; | ||
|
Nishida, Yasunori (Nishida, Y) |
|
|
[JCR상위 1.7] ATTRACTION-5: A phase 3 study of nivolumab plus chemotherapy as postoperative adjuvant treatment for pathological stage III (pStage III) gastric or gastroesophageal junction (G/GEJ) cancer | SCIE | 1.7 | ONCOLOGY | ||||
|
No, Jae Hong (No, JH) |
|
|
[JCR상위 1.7] Oregovomab and non-platinum chemotherapy in PARP inhibitor-resistant ovarian, fallopian tube, or primary peritoneal cancer patients not candidates for platinum retreatment: A multicenter, two-cohort, single-arm phase 2 trial (OPERA/KGOG 3065/APGOT-OV6) | SCIE | 1.7 | ONCOLOGY | ||||
|
Noh, Hyun-Ho (Noh, HH) |
Natl Inst Agr Sci, Rural Dev Adm, Dept Agrofood Safety & Crop Protect, Residual Agrochem Assessment Div, Wonju, South Korea |
|
|
[JCR상위 1.7] Airborne hyperspectral imaging for early diagnosis of kimchi cabbage downy mildew using 3D-ResNet and leaf segmentation | SCIE | 1.7 | AGRICULTURE, MULTIDISCIPLINARY;COMPUTER SCIENCE, INTERDISCIPLINARY APPLICATIONS | hanxiongzhe@kangwon.ac.kr; | ||
|
Oh, Do-Youn (Oh, DY) |
Seoul Natl Univ, Seoul Natl Univ Hosp, Grad Sch, Canc Res Inst,Coll Med,Integrated Major Innovat M, Seoul, South Korea |
|
|
[JCR상위 1.7] Phase 2 study of bavituximab (bavi), a first-in-class antibody targeting phosphatidylserine (PS), plus pembrolizumab (P) in advanced gastric or gastroesophageal junction (GEJ) cancer [JCR상위 74.7] Circulating Tumor DNA as a Predictive Biomarker for Clinical Outcomes With Margetuximab and Pembrolizumab in Pretreated HER2-Positive Gastric/Gastroesophageal Adenocarcinoma |
SCIE | 1.7 | ONCOLOGY | ykkang@amc.seoul.kr; | ||
|
Oh, Min-Wook (Oh, MW) |
Hanbat Natl Univ, Dept Mat Sci & Engn, 125 Dongseodae Ro, Daejeon 34158, South Korea |
|
|
[JCR상위 1.7] Enhanced thermoelectric properties of NbCoSn half-Heuslers through in-situ nanocrystallization of amorphous precursors during the consolidation process | SCIE | 1.7 | MATERIALS SCIENCE, MULTIDISCIPLINARY;METALLURGY & METALLURGICAL ENGINEERING | yish@knu.ac.kr;p.choi@kaist.ac.kr; | ||
|
Oh, Sung Yong (Oh, SY) |
|
|
[JCR상위 1.7] Phase 2 study of bavituximab (bavi), a first-in-class antibody targeting phosphatidylserine (PS), plus pembrolizumab (P) in advanced gastric or gastroesophageal junction (GEJ) cancer | SCIE | 1.7 | ONCOLOGY | ||||
|
Oh, Youjin (Oh, Y) |
|
|
[JCR상위 1.7] Machine learning models based on radiomics features to predict treatment response, biomarker status, and bone metastasis in patients with non-small cell lung cancer (NSCLC) treated with immune checkpoint inhibitors (ICIs) | SCIE | 1.7 | ONCOLOGY | ||||
|
Olowokure, Olugbenga Olanrele (Olowokure, OO) |
|
|
[JCR상위 1.7] Phase 2 study of bavituximab (bavi), a first-in-class antibody targeting phosphatidylserine (PS), plus pembrolizumab (P) in advanced gastric or gastroesophageal junction (GEJ) cancer | SCIE | 1.7 | ONCOLOGY | ||||
|
Omori, Takeshi (Omori, T) |
|
|
[JCR상위 1.7] ATTRACTION-5: A phase 3 study of nivolumab plus chemotherapy as postoperative adjuvant treatment for pathological stage III (pStage III) gastric or gastroesophageal junction (G/GEJ) cancer | SCIE | 1.7 | ONCOLOGY | ||||
|
Orbegoso, Cecilia (Orbegoso, C) |
|
|
[JCR상위 1.7] Trastuzumab deruxtecan (T-DXd) vs treatment of physician's choice (TPC) in patients (pts) with HER2-low, hormone receptor-positive (HR plus ) unresectable and/or metastatic breast cancer (mBC): Exploratory biomarker analysis of DESTINY-Breast04 | SCIE | 1.7 | ONCOLOGY |
페이지 이동: